Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] The company is a distributor for many giant pharma companies and has been doing well for the reported periods. Based on FY23 earnings, the issue appears aggressively priced. Well-informed investors may park funds for the medium to long-term rewards. Read detail review...
Mono Pharmacare Limited peer comparison with similar listed entities. (Standalone) (As on March 31, 2023)
| Company Name | EPS (Rs) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | |
|---|---|---|---|---|---|
| EPS Basic | EPS Diluted | ||||
| Mono Pharmacare Limited | 1.99 | 1.99 | 19.92 | 9.01 | |
| Chandra Bhagat Pharma Limited | 1.20 | 1.20 | 36.42 | 112.50 | 3.29 |
Notes:
Mono Pharmacare IPO Reviews, analysis and views by popular members. Read Mono Pharmacare Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
RHP